Reply: Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy

Lisa Iversen; Philip C. Hannaford; Shona Fielding

doi:10.1016/j.ajog.2017.05.006

Reply: Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy

Lisa Iversen, Philip C. Hannaford, Shona Fielding

Research output: Contribution to journal › Comment/debate

Abstract

We thank Dr Grant for her continued interest in our study. The Royal College of General Practitioners’ (RCGP) Oral Contraception Study has prospectively followed up women forward in time, with information about oral contraceptive (OC) exposure collected often many years before the diagnosis of cancer.

Original language	English
Pages (from-to)	233
Number of pages	1
Journal	American Journal of Obstetrics and Gynecology
Volume	217
Issue number	2
Early online date	11 May 2017
DOIs	https://doi.org/10.1016/j.ajog.2017.05.006
Publication status	Published - Aug 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajog.2017.05.006Licence: Unspecified

Cite this

@article{b05ac92a5bd84b999727677eeeb489f1,

title = "Reply: Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy",

abstract = "We thank Dr Grant for her continued interest in our study. The Royal College of General Practitioners{\textquoteright} (RCGP) Oral Contraception Study has prospectively followed up women forward in time, with information about oral contraceptive (OC) exposure collected often many years before the diagnosis of cancer. ",

author = "Lisa Iversen and Hannaford, {Philip C.} and Shona Fielding",

year = "2017",

month = aug,

doi = "10.1016/j.ajog.2017.05.006",

language = "English",

volume = "217",

pages = "233",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Mosby/Elsevier,",

number = "2",

}

TY - JOUR

T1 - Reply

T2 - Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy

AU - Iversen, Lisa

AU - Hannaford, Philip C.

AU - Fielding, Shona

PY - 2017/8

Y1 - 2017/8

N2 - We thank Dr Grant for her continued interest in our study. The Royal College of General Practitioners’ (RCGP) Oral Contraception Study has prospectively followed up women forward in time, with information about oral contraceptive (OC) exposure collected often many years before the diagnosis of cancer.

AB - We thank Dr Grant for her continued interest in our study. The Royal College of General Practitioners’ (RCGP) Oral Contraception Study has prospectively followed up women forward in time, with information about oral contraceptive (OC) exposure collected often many years before the diagnosis of cancer.

U2 - 10.1016/j.ajog.2017.05.006

DO - 10.1016/j.ajog.2017.05.006

M3 - Comment/debate

C2 - 28502752

SN - 0002-9378

VL - 217

SP - 233

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

IS - 2

ER -

Reply: Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this